Richard Markus - 23 Jan 2026 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role: Chief Medical Officer
Signature: /s/ Carolyn Tang, Attorney-in-Fact
Issuer symbol: RCUS
Transactions as of: 23 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 26 Jan 2026, 20:21:53 UTC
Previous filing: 18 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Markus Richard	Chief Medical Officer	C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY, HAYWARD	/s/ Carolyn Tang, Attorney-in-Fact	26 Jan 2026	0002056093

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RCUS	Common Stock	Award	$0	+24,000	+37%	$0.000000	89,647	23 Jan 2026	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RCUS	Stock Option (right to buy)	Award	$0	+96,000		$0.000000	96,000	23 Jan 2026	Common Stock	96,000	$22.13	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the grant of restricted stock units that vest in four equal annual installments beginning December 15, 2026, subject to the Reporting Person's continued service to the Company.
F2	Includes the unvested portion of the Reporting Person's RSU grants.
F3	The option becomes exercisable in 48 equal monthly installments after January 1, 2026, subject to the Reporting Person's continued service to the Company.